{"pmid":32318328,"pmcid":"PMC7169934","title":"D3Targets-2019-nCoV: a webserver for predicting drug targets and for multi-target and multi-site based virtual screening against COVID-19.","text":["D3Targets-2019-nCoV: a webserver for predicting drug targets and for multi-target and multi-site based virtual screening against COVID-19.","A highly effective medicine is urgently required to cure coronavirus disease 2019 (COVID-19). For the purpose, we developed a molecular docking based webserver, namely D3Targets-2019-nCoV, with two functions, one is for predicting drug targets for drugs or active compounds observed from clinic or in vitro/in vivo studies, the other is for identifying lead compounds against potential drug targets via docking. This server has its unique features, (1) the potential target proteins and their different conformations involving in the whole process from virus infection to replication and release were included as many as possible; (2) all the potential ligand-binding sites with volume larger than 200 A(3) on a protein structure were identified for docking; (3) correlation information among some conformations or binding sites was annotated; (4) it is easily to be updated, and is accessible freely to public (https://www.d3pharma.com/D3Targets-2019-nCoV/index.php). Currently, the webserver contains 42 proteins [20 severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) encoded proteins and 22 human proteins involved in virus infection, replication and release] with 69 different conformations/structures and 557 potential ligand-binding pockets in total. With 6 examples, we demonstrated that the webserver should be useful to medicinal chemists, pharmacologists and clinicians for efficiently discovering or developing effective drugs against the SARS-CoV-2 to cure COVID-19.","Acta Pharm Sin B","Shi, Yulong","Zhang, Xinben","Mu, Kaijie","Peng, Cheng","Zhu, Zhengdan","Wang, Xiaoyu","Yang, Yanqing","Xu, Zhijian","Zhu, Weiliang","32318328"],"abstract":["A highly effective medicine is urgently required to cure coronavirus disease 2019 (COVID-19). For the purpose, we developed a molecular docking based webserver, namely D3Targets-2019-nCoV, with two functions, one is for predicting drug targets for drugs or active compounds observed from clinic or in vitro/in vivo studies, the other is for identifying lead compounds against potential drug targets via docking. This server has its unique features, (1) the potential target proteins and their different conformations involving in the whole process from virus infection to replication and release were included as many as possible; (2) all the potential ligand-binding sites with volume larger than 200 A(3) on a protein structure were identified for docking; (3) correlation information among some conformations or binding sites was annotated; (4) it is easily to be updated, and is accessible freely to public (https://www.d3pharma.com/D3Targets-2019-nCoV/index.php). Currently, the webserver contains 42 proteins [20 severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) encoded proteins and 22 human proteins involved in virus infection, replication and release] with 69 different conformations/structures and 557 potential ligand-binding pockets in total. With 6 examples, we demonstrated that the webserver should be useful to medicinal chemists, pharmacologists and clinicians for efficiently discovering or developing effective drugs against the SARS-CoV-2 to cure COVID-19."],"journal":"Acta Pharm Sin B","authors":["Shi, Yulong","Zhang, Xinben","Mu, Kaijie","Peng, Cheng","Zhu, Zhengdan","Wang, Xiaoyu","Yang, Yanqing","Xu, Zhijian","Zhu, Weiliang"],"date":"2020-04-23T11:00:00Z","year":2020,"_id":"32318328","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.apsb.2020.04.006","keywords":["covid-19","d3targets-2019-ncov","multi-conformation","multi-site","sars-cov-2","target prediction","docking"],"source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1664815087685206016,"score":8.518259,"similar":[{"pmid":32292689,"pmcid":"PMC7102550","title":"Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods.","text":["Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods.","SARS-CoV-2 has caused tens of thousands of infections and more than one thousand deaths. There are currently no registered therapies for treating coronavirus infections. Because of time consuming process of new drug development, drug repositioning may be the only solution to the epidemic of sudden infectious diseases. We systematically analyzed all the proteins encoded by SARS-CoV-2 genes, compared them with proteins from other coronaviruses, predicted their structures, and built 19 structures that could be done by homology modeling. By performing target-based virtual ligand screening, a total of 21 targets (including two human targets) were screened against compound libraries including ZINC drug database and our own database of natural products. Structure and screening results of important targets such as 3-chymotrypsin-like protease (3CLpro), Spike, RNA-dependent RNA polymerase (RdRp), and papain like protease (PLpro) were discussed in detail. In addition, a database of 78 commonly used anti-viral drugs including those currently on the market and undergoing clinical trials for SARS-CoV-2 was constructed. Possible targets of these compounds and potential drugs acting on a certain target were predicted. This study will provide new lead compounds and targets for further in vitro and in vivo studies of SARS-CoV-2, new insights for those drugs currently ongoing clinical studies, and also possible new strategies for drug repositioning to treat SARS-CoV-2 infections.","Acta Pharm Sin B","Wu, Canrong","Liu, Yang","Yang, Yueying","Zhang, Peng","Zhong, Wu","Wang, Yali","Wang, Qiqi","Xu, Yang","Li, Mingxue","Li, Xingzhou","Zheng, Mengzhu","Chen, Lixia","Li, Hua","32292689"],"abstract":["SARS-CoV-2 has caused tens of thousands of infections and more than one thousand deaths. There are currently no registered therapies for treating coronavirus infections. Because of time consuming process of new drug development, drug repositioning may be the only solution to the epidemic of sudden infectious diseases. We systematically analyzed all the proteins encoded by SARS-CoV-2 genes, compared them with proteins from other coronaviruses, predicted their structures, and built 19 structures that could be done by homology modeling. By performing target-based virtual ligand screening, a total of 21 targets (including two human targets) were screened against compound libraries including ZINC drug database and our own database of natural products. Structure and screening results of important targets such as 3-chymotrypsin-like protease (3CLpro), Spike, RNA-dependent RNA polymerase (RdRp), and papain like protease (PLpro) were discussed in detail. In addition, a database of 78 commonly used anti-viral drugs including those currently on the market and undergoing clinical trials for SARS-CoV-2 was constructed. Possible targets of these compounds and potential drugs acting on a certain target were predicted. This study will provide new lead compounds and targets for further in vitro and in vivo studies of SARS-CoV-2, new insights for those drugs currently ongoing clinical studies, and also possible new strategies for drug repositioning to treat SARS-CoV-2 infections."],"journal":"Acta Pharm Sin B","authors":["Wu, Canrong","Liu, Yang","Yang, Yueying","Zhang, Peng","Zhong, Wu","Wang, Yali","Wang, Qiqi","Xu, Yang","Li, Mingxue","Li, Xingzhou","Zheng, Mengzhu","Chen, Lixia","Li, Hua"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32292689","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.apsb.2020.02.008","keywords":["3clpro, 3-chymotrypsin-like protease","drug repurposing","e, envelope","homology modeling","m, membrane protein","molecular docking","n, nucleocapsid protein","nsp, non-structure protein","orf, open reading frame","pdb, protein data bank","rdrp, rna-dependence rna polymerase","remdesivir","s, spike","sars-cov-2","sud, sars unique domain","ub, ubiquitin-like domain"],"source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1664636192728023041,"score":481.94016},{"pmid":32306822,"title":"Peptide-like and small-molecule inhibitors against Covid-19.","text":["Peptide-like and small-molecule inhibitors against Covid-19.","Coronavirus disease strain (SARS-CoV-2) was discovered in 2019, and it is spreading very fast around the world causing the disease Covid-19. Currently, more than 1.6 million individuals are infected, and several thousand are dead across the globe because of Covid-19. Here, we utilized the in-silico approaches to identify possible protease inhibitors against SARS-CoV-2. Potential compounds were screened from the CHEMBL database, ZINC database, FDA approved drugs and molecules under clinical trials. Our study is based on 6Y2F and 6W63 co-crystallized structures available in the protein data bank (PDB). Seven hundred compounds from ZINC/CHEMBL databases and fourteen hundred compounds from drug-bank were selected based on positive interactions with the reported binding site. All the selected compounds were subjected to standard-precision (SP) and extra-precision (XP) mode of docking. Generated docked poses were carefully visualized for known interactions within the binding site. Molecular mechanics-generalized born surface area (MM-GBSA) calculations were performed to screen the best compounds based on docking scores and binding energy values. Molecular dynamics (MD) simulations were carried out on four selected compounds from the CHEMBL database to validate the stability and interactions. MD simulations were also performed on the PDB structure 6YF2F to understand the differences between screened molecules and co-crystallized ligand. We screened 300 potential compounds from various databases, and 66 potential compounds from FDA approved drugs. Cobicistat, ritonavir, lopinavir, and darunavir are in the top screened molecules from FDA approved drugs. The screened drugs and molecules may be helpful in fighting with SARS-CoV-2 after further studies.","J Biomol Struct Dyn","Pant, Suyash","Singh, Meenakshi","Ravichandiran, V","Murty, U S N","Srivastava, Hemant Kumar","32306822"],"abstract":["Coronavirus disease strain (SARS-CoV-2) was discovered in 2019, and it is spreading very fast around the world causing the disease Covid-19. Currently, more than 1.6 million individuals are infected, and several thousand are dead across the globe because of Covid-19. Here, we utilized the in-silico approaches to identify possible protease inhibitors against SARS-CoV-2. Potential compounds were screened from the CHEMBL database, ZINC database, FDA approved drugs and molecules under clinical trials. Our study is based on 6Y2F and 6W63 co-crystallized structures available in the protein data bank (PDB). Seven hundred compounds from ZINC/CHEMBL databases and fourteen hundred compounds from drug-bank were selected based on positive interactions with the reported binding site. All the selected compounds were subjected to standard-precision (SP) and extra-precision (XP) mode of docking. Generated docked poses were carefully visualized for known interactions within the binding site. Molecular mechanics-generalized born surface area (MM-GBSA) calculations were performed to screen the best compounds based on docking scores and binding energy values. Molecular dynamics (MD) simulations were carried out on four selected compounds from the CHEMBL database to validate the stability and interactions. MD simulations were also performed on the PDB structure 6YF2F to understand the differences between screened molecules and co-crystallized ligand. We screened 300 potential compounds from various databases, and 66 potential compounds from FDA approved drugs. Cobicistat, ritonavir, lopinavir, and darunavir are in the top screened molecules from FDA approved drugs. The screened drugs and molecules may be helpful in fighting with SARS-CoV-2 after further studies."],"journal":"J Biomol Struct Dyn","authors":["Pant, Suyash","Singh, Meenakshi","Ravichandiran, V","Murty, U S N","Srivastava, Hemant Kumar"],"date":"2020-04-21T11:00:00Z","year":2020,"_id":"32306822","week":"202017|Apr 20 - Apr 26","doi":"10.1080/07391102.2020.1757510","keywords":["covid-19","drug repurposing","md simulations","virtual screening"],"source":"PubMed","topics":["Treatment","Mechanism"],"weight":1,"e_drugs":["Lopinavir","Cobicistat","Ritonavir","Darunavir"],"_version_":1664632501495136256,"score":445.579},{"pmid":32266867,"title":"In-silico homology assisted identification of inhibitor of RNA binding against 2019-nCoV N-protein (N terminal domain).","text":["In-silico homology assisted identification of inhibitor of RNA binding against 2019-nCoV N-protein (N terminal domain).","The N terminal domain (NTD) of Nucleocapsid protein (N protein) of coronavirus (CoV) binds to the viral (+) sense RNA and results in CoV ribonucleoprotien (CoV RNP) complex, essential for the virus replication. In this study, the RNA-binding N terminal domain (NTD) of the N protein was targeted for the identification of possible inhibitors of RNA binding. Two NTD structures of N proteins were selected (2OFZ and 1SSK, 92% homology) for virtual screening of 56,079 compounds from Asinex and Maybridge library to identify top 15 hits for each of the targets based on \"docking score\". These top-hits were further screened for MM-GBSA binding free energy, pharmacokinetic properties (QikProp) and drug-likeness (SwissADME) and subjected to molecular dynamics (MD) studies. Two suitable binders (ZINC00003118440 and ZINC0000146942) against the target 2OFZ were identified. ZINC00003118440 is a theophylline derivative under the drug class 'bronchodilEtors' and further screening with approved bronchodilators was also studied to identify their ability to bind to the RNA binding region on the N protein. The other identified top hit is ZINC0000146942, which is a 3,4dihydropyrimidone class molecule. Hence this study suggests two important class of compounds, theophylline and pyrimidone derivaties as possible inhibitors of RNA binding to the N terminal domain of N protein of coronavirus, thus opening new avenues for in vitro validations.","J Biomol Struct Dyn","Sarma, Phulen","Sekhar, Nishant","Prajapat, Manisha","Avti, Pramod","Kaur, Hardeep","Kumar, Subodh","Singh, Sanjay","Kumar, Harish","Prakash, Ajay","Dhibar, Deba Prasad","Medhi, Bikash","32266867"],"abstract":["The N terminal domain (NTD) of Nucleocapsid protein (N protein) of coronavirus (CoV) binds to the viral (+) sense RNA and results in CoV ribonucleoprotien (CoV RNP) complex, essential for the virus replication. In this study, the RNA-binding N terminal domain (NTD) of the N protein was targeted for the identification of possible inhibitors of RNA binding. Two NTD structures of N proteins were selected (2OFZ and 1SSK, 92% homology) for virtual screening of 56,079 compounds from Asinex and Maybridge library to identify top 15 hits for each of the targets based on \"docking score\". These top-hits were further screened for MM-GBSA binding free energy, pharmacokinetic properties (QikProp) and drug-likeness (SwissADME) and subjected to molecular dynamics (MD) studies. Two suitable binders (ZINC00003118440 and ZINC0000146942) against the target 2OFZ were identified. ZINC00003118440 is a theophylline derivative under the drug class 'bronchodilEtors' and further screening with approved bronchodilators was also studied to identify their ability to bind to the RNA binding region on the N protein. The other identified top hit is ZINC0000146942, which is a 3,4dihydropyrimidone class molecule. Hence this study suggests two important class of compounds, theophylline and pyrimidone derivaties as possible inhibitors of RNA binding to the N terminal domain of N protein of coronavirus, thus opening new avenues for in vitro validations."],"journal":"J Biomol Struct Dyn","authors":["Sarma, Phulen","Sekhar, Nishant","Prajapat, Manisha","Avti, Pramod","Kaur, Hardeep","Kumar, Subodh","Singh, Sanjay","Kumar, Harish","Prakash, Ajay","Dhibar, Deba Prasad","Medhi, Bikash"],"date":"2020-04-09T11:00:00Z","year":2020,"_id":"32266867","week":"202015|Apr 06 - Apr 12","doi":"10.1080/07391102.2020.1753580","keywords":["2019 novel corona virus","2019-ncov","n terminal domain","nucleocapsid protein","rna binding","sars-cov-2","drug design"],"source":"PubMed","topics":["Mechanism","Treatment"],"weight":1,"locations":["Nucleocapsid"],"e_drugs":["Pyrimidinones","Theophylline"],"_version_":1664637636110712832,"score":445.50577},{"pmid":32329408,"title":"Discovery of Potential Multi-Target-Directed Ligands by Targeting Host-specific SARS-CoV-2 Structurally Conserved Main Protease($).","text":["Discovery of Potential Multi-Target-Directed Ligands by Targeting Host-specific SARS-CoV-2 Structurally Conserved Main Protease($).","Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has resulted in the current COVID-19 pandemic. Worldwide this disease has infected over 2.5 million individuals with a mortality rate ranging from 5 to 10%. There are several efforts are going on in the drug discovery to control the SARS-CoV-2 viral infection. The main protease (M(Pro)) plays a critical role in viral replication and maturation, thus can serve as the primary drug target. To understand the structural evolution of M(Pro), we have performed phylogenetic and Sequence Similarity Network analysis, that depicted divergence of Coronaviridae M(Pro) in five clusters specific to viral hosts. This clustering was corroborated with the comparison of M(Pro) structures. Furthermore, it has been observed that backbone and binding site conformations are conserved despite variation in some of the residues. These attributes can be exploited to repurpose available viral protease inhibitors against SARS-CoV-2 M(Pro). In agreement with this, we performed screening of approximately 7100 molecules including active ingredients present in the Ayurvedic anti-tussive medicines, anti-viral phytochemicals and synthetic anti-virals against SARS-CoV-2 M(Pro) as the primary target. We identified several natural molecules like delta-viniferin, myricitrin, taiwanhomoflavone A, lactucopicrin 15-oxalate, nympholide A, afzelin, biorobin, hesperidin and phyllaemblicin B that strongly binds to SARS-CoV-2 M(Pro). Intrestingly, these molecules also showed strong binding with other potential targets of SARS-CoV-2 infection like viral receptor human angiotensin-converting enzyme 2 (hACE-2) and RNA dependent RNA polymerase (RdRp). We anticipate that our approach for identification of multi-target-directed ligand will provide new avenues for drug discovery against SARS-CoV-2 infection.","J Biomol Struct Dyn","Joshi, Rakesh S","Jagdale, Shounak S","Bansode, Sneha B","Shankar, S Shiva","Tellis, Meenakshi B","Pandya, Vaibhav Kumar","Chugh, Anita","Giri, Ashok P","Kulkarni, Mahesh J","32329408"],"abstract":["Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has resulted in the current COVID-19 pandemic. Worldwide this disease has infected over 2.5 million individuals with a mortality rate ranging from 5 to 10%. There are several efforts are going on in the drug discovery to control the SARS-CoV-2 viral infection. The main protease (M(Pro)) plays a critical role in viral replication and maturation, thus can serve as the primary drug target. To understand the structural evolution of M(Pro), we have performed phylogenetic and Sequence Similarity Network analysis, that depicted divergence of Coronaviridae M(Pro) in five clusters specific to viral hosts. This clustering was corroborated with the comparison of M(Pro) structures. Furthermore, it has been observed that backbone and binding site conformations are conserved despite variation in some of the residues. These attributes can be exploited to repurpose available viral protease inhibitors against SARS-CoV-2 M(Pro). In agreement with this, we performed screening of approximately 7100 molecules including active ingredients present in the Ayurvedic anti-tussive medicines, anti-viral phytochemicals and synthetic anti-virals against SARS-CoV-2 M(Pro) as the primary target. We identified several natural molecules like delta-viniferin, myricitrin, taiwanhomoflavone A, lactucopicrin 15-oxalate, nympholide A, afzelin, biorobin, hesperidin and phyllaemblicin B that strongly binds to SARS-CoV-2 M(Pro). Intrestingly, these molecules also showed strong binding with other potential targets of SARS-CoV-2 infection like viral receptor human angiotensin-converting enzyme 2 (hACE-2) and RNA dependent RNA polymerase (RdRp). We anticipate that our approach for identification of multi-target-directed ligand will provide new avenues for drug discovery against SARS-CoV-2 infection."],"journal":"J Biomol Struct Dyn","authors":["Joshi, Rakesh S","Jagdale, Shounak S","Bansode, Sneha B","Shankar, S Shiva","Tellis, Meenakshi B","Pandya, Vaibhav Kumar","Chugh, Anita","Giri, Ashok P","Kulkarni, Mahesh J"],"date":"2020-04-25T11:00:00Z","year":2020,"_id":"32329408","week":"202017|Apr 20 - Apr 26","doi":"10.1080/07391102.2020.1760137","keywords":["covid-19","coronavirus","mpro","multi-target-directed ligand","protease inhibitor","rdrp","sars-cov-2 virus","hace-2"],"source":"PubMed","topics":["Treatment","Mechanism"],"weight":1,"locations":["M(Pro","M(Pro","M(Pro","afzelin","biorobin"],"e_drugs":["Hesperidin","taiwanhomoflavone A","phyllaemblicin B","myricitrin","delta-viniferin","afzelin"],"_version_":1664996914866683904,"score":435.3569},{"pmid":32266873,"title":"Targeting SARS-CoV-2: a systematic drug repurposing approach to identify promising inhibitors against 3C-like proteinase and 2'-O-ribose methyltransferase.","text":["Targeting SARS-CoV-2: a systematic drug repurposing approach to identify promising inhibitors against 3C-like proteinase and 2'-O-ribose methyltransferase.","The recent pandemic associated with SARS-CoV-2, a virus of the Coronaviridae family, has resulted in an unprecedented number of infected people. The highly contagious nature of this virus makes it imperative for us to identify promising inhibitors from pre-existing antiviral drugs. Two druggable targets, namely 3C-like proteinase (3CLpro) and 2'-O-ribose methyltransferase (2'-O-MTase) were selected in this study due to their indispensable nature in the viral life cycle. 3CLpro is a cysteine protease responsible for the proteolysis of replicase polyproteins resulting in the formation of various functional proteins, whereas 2'-O-MTase methylates the ribose 2'-O position of the first and second nucleotide of viral mRNA, which sequesters it from the host immune system. The selected drug target proteins were screened against an in-house library of 123 antiviral drugs. Two promising drug molecules were identified for each protein based on their estimated free energy of binding (DeltaG), the orientation of drug molecules in the active site and the interacting residues. The selected protein-drug complexes were then subjected to MD simulation, which consists of various structural parameters to equivalently reflect their physiological state. From the virtual screening results, two drug molecules were selected for each drug target protein [Paritaprevir (DeltaG = -9.8 kcal/mol) & Raltegravir (DeltaG = -7.8 kcal/mol) for 3CLpro and Dolutegravir (DeltaG = -9.4 kcal/mol) and Bictegravir (DeltaG = -8.4 kcal/mol) for 2'-OMTase]. After the extensive computational analysis, we proposed that Raltegravir, Paritaprevir, Bictegravir and Dolutegravir are excellent lead candidates for these crucial proteins and they could become potential therapeutic drugs against SARS-CoV-2. Communicated by Ramaswamy H. Sarma.","J Biomol Struct Dyn","Khan, Rameez Jabeer","Jha, Rajat Kumar","Amera, Gizachew Muluneh","Jain, Monika","Singh, Ekampreet","Pathak, Amita","Singh, Rashmi Prabha","Muthukumaran, Jayaraman","Singh, Amit Kumar","32266873"],"abstract":["The recent pandemic associated with SARS-CoV-2, a virus of the Coronaviridae family, has resulted in an unprecedented number of infected people. The highly contagious nature of this virus makes it imperative for us to identify promising inhibitors from pre-existing antiviral drugs. Two druggable targets, namely 3C-like proteinase (3CLpro) and 2'-O-ribose methyltransferase (2'-O-MTase) were selected in this study due to their indispensable nature in the viral life cycle. 3CLpro is a cysteine protease responsible for the proteolysis of replicase polyproteins resulting in the formation of various functional proteins, whereas 2'-O-MTase methylates the ribose 2'-O position of the first and second nucleotide of viral mRNA, which sequesters it from the host immune system. The selected drug target proteins were screened against an in-house library of 123 antiviral drugs. Two promising drug molecules were identified for each protein based on their estimated free energy of binding (DeltaG), the orientation of drug molecules in the active site and the interacting residues. The selected protein-drug complexes were then subjected to MD simulation, which consists of various structural parameters to equivalently reflect their physiological state. From the virtual screening results, two drug molecules were selected for each drug target protein [Paritaprevir (DeltaG = -9.8 kcal/mol) & Raltegravir (DeltaG = -7.8 kcal/mol) for 3CLpro and Dolutegravir (DeltaG = -9.4 kcal/mol) and Bictegravir (DeltaG = -8.4 kcal/mol) for 2'-OMTase]. After the extensive computational analysis, we proposed that Raltegravir, Paritaprevir, Bictegravir and Dolutegravir are excellent lead candidates for these crucial proteins and they could become potential therapeutic drugs against SARS-CoV-2. Communicated by Ramaswamy H. Sarma."],"journal":"J Biomol Struct Dyn","authors":["Khan, Rameez Jabeer","Jha, Rajat Kumar","Amera, Gizachew Muluneh","Jain, Monika","Singh, Ekampreet","Pathak, Amita","Singh, Rashmi Prabha","Muthukumaran, Jayaraman","Singh, Amit Kumar"],"date":"2020-04-09T11:00:00Z","year":2020,"_id":"32266873","week":"202015|Apr 06 - Apr 12","doi":"10.1080/07391102.2020.1753577","keywords":["2'-o-ribose methyltransferase","3c-like proteinase","drug repurposing","md simulation","sars-cov-2","docking"],"source":"PubMed","topics":["Treatment"],"weight":1,"e_drugs":["Ribose","ABT-450","bictegravir","Raltegravir Potassium","dolutegravir"],"_version_":1664637636106518528,"score":433.14987}]}